[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362351-105":59,"doc-detail-362351-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","neoadjuvant-chemoimmunotherapy-in-non-small-cell-lung-cancer-evolving-resectability-criteria-biomarker-driven-postoperative-management-and-emerging-therapeutic-strategies","Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung Cancer - Evolving Resectability Criteria, Biomarker-Driven Postoperative Management, and Emerging Therapeutic Strategies","","Neoadjuvant chemoimmunotherapy (chemo-IO) has reshaped treatment for resectable non-small cell lung cancer (NSCLC), redefining “resectable” disease and testing surgical boundaries. Trials including CheckMate-816, KEYNOTE-671, and AEGEAN show immune checkpoint blockade with chemotherapy improves pathological response and event-free survival, establishing chemo-IO as a new standard for stage IB–III NSCLC. Emerging complexity comes from integrating radiological, anatomic, and biology-led measures such as immune-mediated regression and ctDNA kinetics, with clearance and pathological response used as surrogates to guide adjuvant therapy while avoiding overtreatment. The future hinges on standardized, biomarker-informed decision frameworks supported by multidisciplinary collaboration.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/neoadjuvant-chemoimmunotherapy-in-non-small-cell-lung-cancer-evolving-resectability-criteria-biomarker-driven-postoperative-management-and-emerging-therapeutic-strategies/362351/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/neoadjuvant-chemoimmunotherapy-in-non-small-cell-lung-cancer-evolving-resectability-criteria-biomarker-driven-postoperative-management-and-emerging-therapeutic-strategies/362351.png","ImageObject",300,407,{"name":92,"@type":93},"Margaret","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How has neoadjuvant chemoimmunotherapy changed the concept of resectable NSCLC?","Question",{"text":112,"@type":113},"Chemo-IO has shifted treatment paradigms by challenging traditional surgical boundaries and redefining what qualifies as “resectable” disease. In this setting, immune-driven downstaging and biology-based responses complement conventional radiological and anatomic criteria.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which clinical trials support the use of neoadjuvant chemo-IO in resectable NSCLC?",{"text":117,"@type":113},"The review highlights major trials such as CheckMate-816, KEYNOTE-671, and AEGEAN, demonstrating improved pathological response and event-free survival with immune checkpoint blockade plus chemotherapy. Additional trial data such as NADIM and NADIM-2 are also cited for high pCR rates.",{"name":119,"@type":110,"acceptedAnswer":120},"What role do biomarkers like ctDNA play in postoperative management and treatment decisions?",{"text":121,"@type":113},"ctDNA clearance and pathological response are described as powerful surrogates for long-term survival. The review notes ongoing studies exploring how ctDNA kinetics could guide adjuvant therapy and reduce overtreatment by integrating biomarkers into surgical and multidisciplinary decision-making.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362351,1790185881,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Open access Review  \n Neoadjuvant chemoimmunotherapy in  \nnon-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies  \nAkshay Patel,1,2 Elliot Wakeam,3 Eleni Josephides,4 Savvas Lampridis,5 Eleni Karapanagiotou,6 Gary Middleton,1 Babu Naidu,7 Marc De Perrot,3 Andrea Bille2  \nTo cite: Patel A, Wakeam E, Josephides E, et al. Neoadjuvant chemoimmunotherapy in non-small cell lung cancer:  \nevolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies. Journal for ImmunoTherapy of Cancer 2026;14:e014098 . doi:10 . 1136/ jitc-2025-014098  \nAP and AB are joint senior authors.  \nAccepted 17 January 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Akshay Patel;  \n[a.patel.2@bham.ac.uk](a.patel.2@bham.ac.uk)  \nABSTRACT  \nNeoadjuvant chemoimmunotherapy (chemo-IO) has fundamentally reshaped the treatment paradigm for resectable non-small cell lung cancer (NSCLC), challenging long-held surgical boundaries and redefining what constitutes “resectable” disease. Trials such as CheckMate-816, KEYNOTE-671, and AEGEAN have demonstrated that integrating immune checkpoint blockade with chemotherapy yields unprecedented rates of pathological response and event-free survival, positioning chemo-IO as the new global standard for stage IB–IIIANSCLC. Yet these advances bring new complexities; how do we define resectability in an era of immunotherapeutic downstaging, and how should multidisciplinary teams adapt to evolving biology? Traditional radiological and anatomic criteria now sit alongside immune-mediated regression and circulating tumor DNA (ctDNA) kineticsas measures of treatment success. ctDNA clearance and pathological response serve as powerful surrogates for long-term survival, with ongoing studies such as MERMAID-1/2 exploring their potential to guide adjuvant therapy and spare overtreatment. The modern challenge lies in integrating these biomarkers into surgical decisionmaking and developing standardized, biology-informed resectability frameworks. Future progress will depend on close collaboration between surgeons, oncologists, and translational scientists to expand surgical candidacy safely and define the next generation of curative strategies in lung cancer.  \nINTRODUCTION  \nNon-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide, with surgical resection offering the best chance of long-term survival in early and locally advanced stages.1–3 Over the past decade, systemic therapy has undergone a paradigm shift from chemotherapy alone to immune checkpoint blockade (ICB) targeting programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1)  \npathways, both in the metastatic and locally advanced disease settings.4 5 This evolution has paved the way for neoadjuvant chemoimmunotherapy (chemo-IO) as a strategy to enhance pathological response, eradicate micrometastatic disease, and improve eventfree survival (EFS) and indeed improve overall survival (OS) .  \nLandmark clinical trials have established the benefit of incorporating immunotherapy into the neoadjuvant setting.6–13 Metaanalytical data has further consolidated trial data and demonstrated EFS and pathological complete response (pCR) benefits at 2 years in the immunotherapy arm.14 TheEFS benefit has also been demonstrated in the chemo-IO arm even at low PDL1 (\u003C1%) expression levels.15 The NADIM and NADIM-2 trials,10 16 conducted in Spain, demonstrated strikingly high rates of pCR approaching 60% and favorable survival outcomes in patients with stage IIIA disease (tumor, node, metastases (TNM) 8), with only N3 involvement being considered as unresectable. The iACORN meta-analysis17 intimated an OS benefit with neoadjuvant chemo-IO ","cbCaisvJBE3MYWWG","https://ap.wps.com/l/cbCaisvJBE3MYWWG","pdf",353099,11,"English","# Abstract\n# Introduction\n## Clinical trial evidence for neoadjuvant chemo-IO\n## Outcome measures and surrogates (EFS, pCR, ctDNA)\n## Resectability definitions and biomarker-informed frameworks","[{\"question\":\"How has neoadjuvant chemoimmunotherapy changed the concept of resectable NSCLC?\",\"answer\":\"Chemo-IO has shifted treatment paradigms by challenging traditional surgical boundaries and redefining what qualifies as “resectable” disease. In this setting, immune-driven downstaging and biology-based responses complement conventional radiological and anatomic criteria.\"},{\"question\":\"Which clinical trials support the use of neoadjuvant chemo-IO in resectable NSCLC?\",\"answer\":\"The review highlights major trials such as CheckMate-816, KEYNOTE-671, and AEGEAN, demonstrating improved pathological response and event-free survival with immune checkpoint blockade plus chemotherapy. Additional trial data such as NADIM and NADIM-2 are also cited for high pCR rates.\"},{\"question\":\"What role do biomarkers like ctDNA play in postoperative management and treatment decisions?\",\"answer\":\"ctDNA clearance and pathological response are described as powerful surrogates for long-term survival. The review notes ongoing studies exploring how ctDNA kinetics could guide adjuvant therapy and reduce overtreatment by integrating biomarkers into surgical and multidisciplinary decision-making.\"}]","Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung Cancer - Evolving Resectability Criteria, Biomarker-Driven Postoperative Management, and Emerging Therapeutic Strategies | PDF",1790147254,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/045be672f98cb221fb81c01a6cd9e6ef.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/434cfc14d583903d56a9554b119e04fe.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d68c73190668739df1b22470e7740066.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6053719c0b267c539c62694293347c36.webp",980,1306]